Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of APIs.

TOKYO--(BUSINESS WIRE)--Japanese pharmaceutical contract development and manufacturing organization (CDMO) Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation (FO–MD) ...

FIIs increased their stakes in IOL Chemicals and Granules India during Q1FY27. Here's why these pharma companies are in focus ...

Discover how the Semaglutide episode could reshape India's generics sector, revealing vulnerabilities and opportunities for ...

Vishal Manchanda, Pharma Analyst at Systematix Group, said semaglutide is a technically complex peptide product, making ...

As the largest pure-play API/CDMO, Divi's should continue benefiting from custom-synthesis order-book conversion and the ...

Divis Laboratories benefits from strong CDMO demand but faces high valuations, prompting a hold recommendation for investors.

The Indian pharma sector anticipates steady growth in FY27, driven by domestic demand and expanding GLP-1 therapy ...

The Indian pharmaceutical sector is expected to maintain a healthy growth trajectory in the coming quarters, supported by ...

The practice of compounding (that is, the preparation, mixing, combining, packaging and labelling of a medicine by, amongst ...

Multiple semaglutide makers have recalled batches or delayed supplies over quality concerns in India. Doctors are seeking transparent explanations as generics now account for most sales in the market.

Three Indian pharmaceutical companies, Dr. Reddy's Laboratories, Torrent Pharmaceuticals and USV, have initiated voluntary ...